BIOMAT Database Logo BIOMAT Database Logo

Reduction of digoxin-induced inotropism during quinidine administration. 1980

E Steiness, and S Waldorff, and P B Hansen, and H Kjaergård, and J Buch, and H Egeblad

A kinetic and dynamic study of digoxin was performed in 6 healthy subjects, and repeated in the same subjects after administration of quinidine for 1 wk. Myocardial performance evaluated by systolic time intervals increased in parallel with plasma digoxin concentration, whereas left ventricular end-diastolic diameter on echocardiography and arterial blood pressure remained constant. The positive inotropic effect of digoxin was abolished during concomitant treatment with quinidine. Quinidine has been reported to increase the risk of digitoxicity, and therefore the treatment with digoxin and quinidine in combination should be reconsidered.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D011802 Quinidine An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission. Adaquin,Apo-Quinidine,Chinidin,Quincardine,Quinidex,Quinidine Sulfate,Quinora,Apo Quinidine,Sulfate, Quinidine
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females

Related Publications

E Steiness, and S Waldorff, and P B Hansen, and H Kjaergård, and J Buch, and H Egeblad
Digoxin bioavailability during quinidine administration.
November 1981, Clinical pharmacology and therapeutics,
E Steiness, and S Waldorff, and P B Hansen, and H Kjaergård, and J Buch, and H Egeblad
Reduction of digoxin effect during the digoxin-quinidine interaction.
March 1984, Clinical pharmacology and therapeutics,
E Steiness, and S Waldorff, and P B Hansen, and H Kjaergård, and J Buch, and H Egeblad
Tissue digoxin concentrations during the quinidine-digoxin interaction.
June 1983, The American journal of cardiology,
E Steiness, and S Waldorff, and P B Hansen, and H Kjaergård, and J Buch, and H Egeblad
Tissue digoxin concentrations and digoxin effect during the quinidine-digoxin interaction.
March 1985, Journal of the American College of Cardiology,
E Steiness, and S Waldorff, and P B Hansen, and H Kjaergård, and J Buch, and H Egeblad
Management of quinidine-induced elevations of serum digoxin.
November 1979, American journal of hospital pharmacy,
E Steiness, and S Waldorff, and P B Hansen, and H Kjaergård, and J Buch, and H Egeblad
Digoxin alters quinidine and quinidine alters digoxin pharmacokinetics in dogs.
March 1980, The Journal of laboratory and clinical medicine,
E Steiness, and S Waldorff, and P B Hansen, and H Kjaergård, and J Buch, and H Egeblad
Enhanced cardiac effect of digoxin during quinidine treatment.
May 1979, Archives of internal medicine,
E Steiness, and S Waldorff, and P B Hansen, and H Kjaergård, and J Buch, and H Egeblad
Quinidine-digoxin interaction.
January 1980, The New England journal of medicine,
E Steiness, and S Waldorff, and P B Hansen, and H Kjaergård, and J Buch, and H Egeblad
Quinidine-digoxin interaction.
January 1980, The New England journal of medicine,
E Steiness, and S Waldorff, and P B Hansen, and H Kjaergård, and J Buch, and H Egeblad
Quinidine-digoxin interaction.
January 1980, The New England journal of medicine,
Copied contents to your clipboard!